TY - JOUR AU - Fang, J. Y. AU - Dong, H. L. AU - Wu, K. S. AU - Du, P. L. AU - Xu, Z. X. AU - Lin, K. PY - 2015 DA - 2015// TI - Characteristics and prediction of lung cancer mortality in China from 1991 to 2013 JO - Asian Pac J Cancer Prev VL - 16 UR - https://doi.org/10.7314/APJCP.2015.16.14.5829 DO - 10.7314/APJCP.2015.16.14.5829 ID - Fang2015 ER - TY - JOUR AU - Han, J. Y. AU - Park, K. AU - Kim, S. W. AU - Lee, D. H. AU - KimHY, K. i. m. H. T. PY - 2012 DA - 2012// TI - First-SIGNAL:first-line single-agent iressa versus gemcitabine and cisplatin trial innever-smokers with adenocarcinoma of the lung JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.8456 DO - 10.1200/JCO.2011.36.8456 ID - Han2012 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. L. AU - Chen, G. AU - Feng, J. AU - Liu, X. Q. AU - Wang, C. PY - 2011 DA - 2011// TI - Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70184-X DO - 10.1016/S1470-2045(11)70184-X ID - Zhou2011 ER - TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. AU - Negoro, S. AU - Okamoto, I. AU - Tsurutani, J. PY - 2010 DA - 2010// TI - West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. AU - Yang, C. H. AU - Chu, D. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Ciuleanu, T. AU - Brodowicz, T. AU - Zielinski, C. AU - Kim, J. H. AU - Krzakowski, M. AU - Laack, E. PY - 2009 DA - 2009// TI - Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study JO - Lancet VL - 374 UR - https://doi.org/10.1016/S0140-6736(09)61497-5 DO - 10.1016/S0140-6736(09)61497-5 ID - Ciuleanu2009 ER - TY - JOUR AU - Paz-Ares, L. AU - Marinis, F. AU - Dediu, M. AU - Thomas, M. AU - Pujol, J. L. AU - Bidoli, P. PY - 2012 DA - 2012// TI - Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70063-3 DO - 10.1016/S1470-2045(12)70063-3 ID - Paz-Ares2012 ER - TY - JOUR AU - Sequist, L. V. AU - Waltman, B. A. AU - Dias-Santagata, D. AU - Digumarthy, S. AU - Turke, A. B. AU - Fidias, P. PY - 2011 DA - 2011// TI - Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors JO - Sci Transl Med. VL - 3 UR - https://doi.org/10.1126/scitranslmed.3002003 DO - 10.1126/scitranslmed.3002003 ID - Sequist2011 ER - TY - JOUR AU - Temel, J. S. AU - Greer, J. A. AU - Muzikansky, A. AU - Gallagher, E. R. AU - Admane, S. AU - Jackson, V. A. PY - 2010 DA - 2010// TI - Early palliative care for patients with metastatic non-small-cell lung cancer JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1000678 DO - 10.1056/NEJMoa1000678 ID - Temel2010 ER - TY - JOUR AU - Zimmermann, C. AU - Swami, N. AU - Krzyzanowska, M. AU - Hannon, B. AU - Leighl, N. AU - Oza, A. PY - 2014 DA - 2014// TI - Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial JO - Lancet VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)62416-2 DO - 10.1016/S0140-6736(13)62416-2 ID - Zimmermann2014 ER - TY - JOUR AU - Muenst, S. AU - Schaerli, A. R. AU - Gao, F. AU - Daster, S. AU - Trella, E. AU - Droeser, R. A. PY - 2014 DA - 2014// TI - Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer JO - Breast Cancer Res Treat. VL - 146 UR - https://doi.org/10.1007/s10549-014-2988-5 DO - 10.1007/s10549-014-2988-5 ID - Muenst2014 ER - TY - JOUR AU - Schalper, K. A. AU - Velcheti, V. AU - Carvajal, D. AU - Wimberly, H. AU - Brown, J. AU - Pusztai, L. AU - Rimm, D. L. PY - 2014 DA - 2014// TI - In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2702 DO - 10.1158/1078-0432.CCR-13-2702 ID - Schalper2014 ER - TY - JOUR AU - Ali, H. R. AU - Glont, S. E. AU - Blows, F. M. AU - Provenzano, E. AU - Dawson, S. J. AU - Liu, B. PY - 2015 DA - 2015// TI - PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes JO - Ann Oncol VL - 26 ID - Ali2015 ER - TY - JOUR AU - Azuma, K. AU - Ota, K. AU - Kawahara, A. AU - Hattori, S. AU - Iwama, E. AU - Harada, T. PY - 2014 DA - 2014// TI - Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu242 DO - 10.1093/annonc/mdu242 ID - Azuma2014 ER - TY - JOUR AU - Brahmer, J. R. AU - Tykodi, S. S. AU - Chow, L. Q. AU - Hwu, W. J. AU - Topalian, S. L. AU - Hwu, P. PY - 2012 DA - 2012// TI - Safety and activity of anti-PD-L1 antibody in patients with advanced cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200694 DO - 10.1056/NEJMoa1200694 ID - Brahmer2012 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Wolfle, S. J. AU - Strebovsky, J. AU - Bartz, H. AU - Sahr, A. AU - Arnold, C. AU - Kaiser, C. PY - 2011 DA - 2011// TI - PD-L1 expression on tolerogenic APCs is controlled by STAT-3 JO - Eur J Immunol. VL - 41 UR - https://doi.org/10.1002/eji.201040979 DO - 10.1002/eji.201040979 ID - Wolfle2011 ER - TY - JOUR AU - Konishi, J. AU - Yamazaki, K. AU - Azuma, M. AU - Kinoshita, I. AU - Dosaka-Akita, H. AU - Nishimura, M. PY - 2004 DA - 2004// TI - B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0428 DO - 10.1158/1078-0432.CCR-04-0428 ID - Konishi2004 ER - TY - JOUR AU - Hirahara, K. AU - Ghoreschi, K. AU - Yang, X. P. AU - Takahashi, H. AU - Laurence, A. AU - Vahedi, G. PY - 2012 DA - 2012// TI - Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1 JO - Immunity. VL - 36 UR - https://doi.org/10.1016/j.immuni.2012.03.024 DO - 10.1016/j.immuni.2012.03.024 ID - Hirahara2012 ER - TY - JOUR AU - Wang, A. AU - Wang, H. Y. AU - Liu, Y. AU - Zhao, M. C. AU - Zhang, H. J. AU - Lu, Z. Y. PY - 2015 DA - 2015// TI - The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis JO - Eur J Surg Oncol VL - 41 UR - https://doi.org/10.1016/j.ejso.2015.01.020 DO - 10.1016/j.ejso.2015.01.020 ID - Wang2015 ER - TY - STD TI - Travis WD, Brambilla E, Muler-Hermelink HK, et al (eds). WHO classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 145–47 ID - ref21 ER - TY - JOUR AU - Wu, C. AU - Zhao, C. AU - Yang, Y. AU - He, Y. AU - Hou, L. AU - Li, X. PY - 2015 DA - 2015// TI - High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules JO - J Thorac Oncol. VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000487 DO - 10.1097/JTO.0000000000000487 ID - Wu2015 ER - TY - JOUR AU - Akbay, E. A. AU - Koyama, S. AU - Carretero, J. AU - Altabef, A. AU - Tchaicha, J. H. AU - Christensen, C. L. PY - 2013 DA - 2013// TI - Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-13-0310 DO - 10.1158/2159-8290.CD-13-0310 ID - Akbay2013 ER - TY - JOUR AU - Zhang, Y. AU - Wang, L. AU - Li, Y. AU - Pan, Y. AU - Wang, R. AU - Hu, H. PY - 2014 DA - 2014// TI - Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma JO - Onco Targets Ther. VL - 7 UR - https://doi.org/10.2147/OTT.S59959 DO - 10.2147/OTT.S59959 ID - Zhang2014 ER - TY - JOUR AU - Mu, C. Y. AU - Huang, J. A. AU - Chen, Y. AU - Chen, C. AU - Zhang, X. G. PY - 2011 DA - 2011// TI - High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation JO - Med Oncol VL - 28 UR - https://doi.org/10.1007/s12032-010-9515-2 DO - 10.1007/s12032-010-9515-2 ID - Mu2011 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Akbay, E. A. AU - Koyama, S. AU - Carretero, J. PY - 2013 DA - 2013// TI - Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-13-0310 DO - 10.1158/2159-8290.CD-13-0310 ID - Akbay2013 ER - TY - JOUR AU - Ota, K. AU - Azuma, K. AU - Kawahara, A. PY - 2015 DA - 2015// TI - Induction of PD-L1 expression by the EML4–ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0016 DO - 10.1158/1078-0432.CCR-15-0016 ID - Ota2015 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Yang, C. Y. AU - Lin, M. W. AU - Chang, Y. L. AU - Wu, C. T. AU - Yang, P. C. PY - 2014 DA - 2014// TI - Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2014.01.018 DO - 10.1016/j.ejca.2014.01.018 ID - Yang2014 ER -